Bristol Myers earnings beat expectations, driven by sales of older drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Leerink Partners
November 4, 2024 6:20 AM ESTLeerink Partners analyst David Risinger raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $55.00 (from $53.00) while maintaining a Market Perform rating.
The analyst comments "Bottom line. We are increasing our PT from $53 (7.5x old 25E EPS of $7.06) to $55 (7.5x new 25E... More
